Optimizing biological therapy in Crohn’s disease

Krisztina Barbara Gecse, Zsuzsanna Végh, P. Lakatos

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Anti-TNF therapy has revolutionized the treatment of inflammatory bowel diseases, including both Crohn’s disease and ulcerative colitis. However, a significant proportion of patients does not respond to anti-TNF agents or lose response over time. Recently, therapeutic drug monitoring has gained a major role in identifying the mechanism and management of loss of response. The aim of this review article is to summarize the predictors of efficacy and outcomes, the different mechanisms of anti-TNF/biological failure in Crohn’s disease and identify strategies to optimize biological treatment.

Original languageEnglish
JournalExpert Review of Gastroenterology and Hepatology
DOIs
Publication statusAccepted/In press - Jan 2 2016

Fingerprint

Biological Therapy
Crohn Disease
Drug Monitoring
Ulcerative Colitis
Inflammatory Bowel Diseases
Therapeutics

Keywords

  • adalimumab
  • Crohn’s disease
  • infliximab
  • therapeutic drug level monitoring
  • ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Optimizing biological therapy in Crohn’s disease. / Gecse, Krisztina Barbara; Végh, Zsuzsanna; Lakatos, P.

In: Expert Review of Gastroenterology and Hepatology, 02.01.2016.

Research output: Contribution to journalArticle

@article{826cb7ce5eb640ccb2f516535f3c182d,
title = "Optimizing biological therapy in Crohn’s disease",
abstract = "Anti-TNF therapy has revolutionized the treatment of inflammatory bowel diseases, including both Crohn’s disease and ulcerative colitis. However, a significant proportion of patients does not respond to anti-TNF agents or lose response over time. Recently, therapeutic drug monitoring has gained a major role in identifying the mechanism and management of loss of response. The aim of this review article is to summarize the predictors of efficacy and outcomes, the different mechanisms of anti-TNF/biological failure in Crohn’s disease and identify strategies to optimize biological treatment.",
keywords = "adalimumab, Crohn’s disease, infliximab, therapeutic drug level monitoring, ulcerative colitis",
author = "Gecse, {Krisztina Barbara} and Zsuzsanna V{\'e}gh and P. Lakatos",
year = "2016",
month = "1",
day = "2",
doi = "10.1586/17474124.2016.1096198",
language = "English",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Optimizing biological therapy in Crohn’s disease

AU - Gecse, Krisztina Barbara

AU - Végh, Zsuzsanna

AU - Lakatos, P.

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Anti-TNF therapy has revolutionized the treatment of inflammatory bowel diseases, including both Crohn’s disease and ulcerative colitis. However, a significant proportion of patients does not respond to anti-TNF agents or lose response over time. Recently, therapeutic drug monitoring has gained a major role in identifying the mechanism and management of loss of response. The aim of this review article is to summarize the predictors of efficacy and outcomes, the different mechanisms of anti-TNF/biological failure in Crohn’s disease and identify strategies to optimize biological treatment.

AB - Anti-TNF therapy has revolutionized the treatment of inflammatory bowel diseases, including both Crohn’s disease and ulcerative colitis. However, a significant proportion of patients does not respond to anti-TNF agents or lose response over time. Recently, therapeutic drug monitoring has gained a major role in identifying the mechanism and management of loss of response. The aim of this review article is to summarize the predictors of efficacy and outcomes, the different mechanisms of anti-TNF/biological failure in Crohn’s disease and identify strategies to optimize biological treatment.

KW - adalimumab

KW - Crohn’s disease

KW - infliximab

KW - therapeutic drug level monitoring

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84945207856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945207856&partnerID=8YFLogxK

U2 - 10.1586/17474124.2016.1096198

DO - 10.1586/17474124.2016.1096198

M3 - Article

C2 - 26471077

AN - SCOPUS:84945207856

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

ER -